Key result
Perindopril-based blood pressure lowering reduced major vascular events by 38% in Asian and 20% in Western participants with cerebrovascular disease.
Why the study?
Does perindopril-based blood pressure lowering reduce major vascular events in Asian and Western patients with cerebrovascular disease?
RCT (n=6,105)
placebo-controlled
randomly assigned
Yes
Does perindopril-based blood pressure lowering reduce major vascular events in Asian and Western patients with cerebrovascular disease?
Perindopril-based blood pressure lowering significantly reduces major vascular events in both Asian and Western patients with cerebrovascular disease, with potentially greater relative risk reductions in Asian patients.
Answers are grounded in this paper and cite their sources.
Supports perindopril-based BP lowering for secondary prevention in cerebrovascular disease; confirms benefit across both Asian and Western populations.
OBJECTIVE: To assess the benefits of blood pressure (BP) lowering on vascular events separately for Asian and for Western participants with particular emphasis on stroke subtypes and cardiac outcomes. METHODS: This is a subsidiary analysis of Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a randomized, placebo-controlled trial that established the benefits of BP lowering in 6105 patients with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, and indapamide for those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). Outcomes are total and cause-specific vascular outcomes. RESULTS: The annual rates for total major vascular events were 4.2% in Asian and 5.2% in Western participants. Overall stroke rates were greater in Asian compared to Western participants with proportionally more lacunar infarctions and haemorrhagic strokes in Asians and more cardio-embolic infarctions and large artery infarctions in Western participants. Active treatment reduced BP by 10.3/4.6 mmHg in Asian, and by 8.1/3.6 mmHg in Western participants. Among Asian participants there was a 38% [95% confidence interval (CI) 23-49%] reduction in major vascular events compared to a 20% (95% CI 7-31%) reduction in Western participants (P homogeneity = 0.06). Similarly, there were higher relative risk reductions for all other outcomes among Asian participants, but this only reached statistical significance for heart failure and vascular death (P = 0.02 for each). The number needed to treat for major vascular events over 5 years was 15 (95% CI 10-26) in Asian compared to 28 (95% CI 17-94) in Western participants (P homogeneity = 0.09). CONCLUSIONS: BP lowering reduces the risk of major vascular events, with separately significant reductions, in both Asia and the West.
No takes yet. Share an insight, caveat, or question.
Arima et al. (2010) conducted an RCT in cerebrovascular disease (n=6,105). Perindopril-based blood pressure lowering (perindopril +/- indapamide) vs. Placebo was evaluated on major vascular events (Relative risk reduction 38% (Asian) vs 20% (Western), 95% CI 23-49% (Asian), 7-31% (Western), p=0.06 for homogeneity). Perindopril-based blood pressure lowering reduced major vascular events by 38% in Asian and 20% in Western participants with cerebrovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: